
In recent years progress has been made in developing cancer immunotherapies that target specific aspects of an individual’s tumour.
moreFor more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalised immunotherapy to people with cancer.
In recent years progress has been made in developing cancer immunotherapies that target specific aspects of an individual’s tumour.
moreRoche’s scientists are leading pioneers in immune biology and cancer research, which is resulting in innovative and personalised treatment options in cancer.
Cancer remains one of the leading causes of death worldwide, but world-class research provides hope.
moreRoche scientists discuss their work at the cutting edge of cancer immunotherapy research
moreRoche CEO Severin Schwan talks about our commitment and leadership in this exciting field.
Learn how biomarkers take the stage in helping doctors diagnose cancer.
moreWhen the body’s own immune system fails, T-cell bispecific antibodies help T-cells spring back into action and attack cancer cells.
Learn how our research and development team managed to separate 200 known cancer types into three primary immune profiles.
The role of the immune system is to protect the body from foreign invaders. PD-L1 can help tumour cells evade the immune surveillance.